(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Instructions to Upgrade the Security Elements of Your Kona SUV- New peace laureate: Iran's arrest of Mohammadi 'confession of fear'
- Solid Propensities: Little Changes for a Superior Life
- Italy now recognizes the crime of femicide and punishes it with life in prison
- Home Mechanization Frameworks for Brilliant Residing
- The capacity to understand people on a profound level: Exploring Life's Intricacies
- Trump signs bill allowing whole milk to return to school lunches
- College students are now slightly less likely to experience severe depression, research shows – but the mental health crisis is far from over
- Analysis-From 'Icarus bug' to flawed panels: Airbus counts cost of relying on single model
